Vanguard Group Inc. lifted its position in shares of Enzo Biochem, Inc. (NYSE:ENZ) by 5.2% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,752,680 shares of the medical research company’s stock after purchasing an additional 86,922 shares during the period. Vanguard Group Inc. owned about 3.78% of Enzo Biochem worth $19,350,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Evermore Global Advisors LLC increased its position in shares of Enzo Biochem by 7.3% during the second quarter. Evermore Global Advisors LLC now owns 3,555,233 shares of the medical research company’s stock worth $39,250,000 after purchasing an additional 242,441 shares in the last quarter. Gilder Gagnon Howe & Co. LLC increased its position in shares of Enzo Biochem by 20.3% during the second quarter. Gilder Gagnon Howe & Co. LLC now owns 999,961 shares of the medical research company’s stock worth $11,040,000 after purchasing an additional 168,607 shares in the last quarter. TIAA CREF Investment Management LLC increased its position in shares of Enzo Biochem by 43.9% during the second quarter. TIAA CREF Investment Management LLC now owns 533,923 shares of the medical research company’s stock worth $5,895,000 after purchasing an additional 162,854 shares in the last quarter. Northern Trust Corp increased its position in shares of Enzo Biochem by 8.8% during the second quarter. Northern Trust Corp now owns 506,879 shares of the medical research company’s stock worth $5,596,000 after purchasing an additional 40,939 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Enzo Biochem by 8.6% during the first quarter. Geode Capital Management LLC now owns 291,119 shares of the medical research company’s stock worth $2,436,000 after purchasing an additional 23,036 shares in the last quarter. Institutional investors and hedge funds own 62.46% of the company’s stock.

ENZ has been the topic of several recent research reports. BidaskClub cut Enzo Biochem from a “hold” rating to a “sell” rating in a research report on Monday, August 14th. Zacks Investment Research cut Enzo Biochem from a “buy” rating to a “hold” rating in a research report on Tuesday, August 15th. Finally, TheStreet cut Enzo Biochem from a “b” rating to a “c+” rating in a research report on Wednesday, September 27th.

Enzo Biochem, Inc. (NYSE:ENZ) opened at $9.20 on Thursday. Enzo Biochem, Inc. has a 52-week low of $6.27 and a 52-week high of $12.04.

ILLEGAL ACTIVITY NOTICE: This piece of content was reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.dailypolitical.com/2017/11/16/enzo-biochem-inc-enz-shares-bought-by-vanguard-group-inc.html.

In related news, CFO Barry W. Weiner sold 54,126 shares of the business’s stock in a transaction dated Wednesday, October 25th. The stock was sold at an average price of $10.11, for a total value of $547,213.86. Following the transaction, the chief financial officer now owns 1,423,367 shares in the company, valued at approximately $14,390,240.37. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Elazar Rabbani sold 72,401 shares of the business’s stock in a transaction dated Wednesday, October 25th. The shares were sold at an average price of $10.09, for a total value of $730,526.09. Following the completion of the transaction, the chief executive officer now owns 2,038,474 shares in the company, valued at approximately $20,568,202.66. The disclosure for this sale can be found here. Insiders sold a total of 191,398 shares of company stock worth $1,925,292 in the last 90 days. 9.50% of the stock is currently owned by insiders.

Enzo Biochem Company Profile

Enzo Biochem, Inc is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company’s segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies.

Institutional Ownership by Quarter for Enzo Biochem (NYSE:ENZ)

Receive News & Ratings for Enzo Biochem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem Inc. and related companies with MarketBeat.com's FREE daily email newsletter.